NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









LabGenius Therapeutics

LabGenius Therapeutics

Private
LondonHealthcare & Life Scienceshttps://labgeniustx.com/

Last Round

Series B

Extension

Feb 16, 2026

Total Funding Raised

$78.1M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

LabGenius Therapeutics is a biotechnology company that develops an AI-driven protein engineering platform to discover and optimize next-generation therapeutic antibodies for solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

antibody discoveryprotein engineeringdrug discoveryAI drug discoveryin silico drug designmultispecific antibodiesclosed-loop discoverysynthetic biologyrobotic automationmachine learningbiotech platformoncology therapeuticslab automationcomputational biologybiopharma R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LabGenius Therapeutics Comparables

Compare LabGenius Therapeutics with similar companies based on industry and business-model similarity.

LabGenius Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BigHat Biosciences
88%
Generate Biomedicines
83%
AbCellera Biologics Inc.
83%

LabGenius Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionFeb 16, 2026
Series BMay 21, 2024
GrantNov 30, 2022
GrantOct 7, 2022
Series A ExtensionOct 29, 2020
Series A
Oct 24, 2019

Key People

Founding team and executive leadership

James Field

CEO Founder

Founding Team

LabGenius Therapeutics Investors

Notable investors and investment history

LabGenius Therapeutics investors
InvestorRounds
Innovate UKGrant
Backed VCSeed
System.OneSeed
Inovia CapitalSeries A, Series A Extension
Air Street CapitalSeries A
Acequia CapitalSeed
M VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 25, 2026

    Monthly visitors increased 180% MoM, reaching 3.1K.

  • Apr 17, 2026

    Presenting preclinical data at AACR Annual Meeting 2026.

LabGenius Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

LabGenius Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about LabGenius Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range66
Year Founded2012
Last FundingFeb 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.